Cargando…

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer

ER positive (ER+) and HER2 negative (HER2-) breast cancers are routinely treated based on estrogen dependence. CDK4/6 inhibitors in combination with endocrine therapy have significantly improved the progression-free survival of patients with ER+/HER2- metastatic breast cancer. Gene expression profil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knudsen, Erik S., Witkiewicz, Agnieszka K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342463/ https://www.ncbi.nlm.nih.gov/pubmed/27564114 http://dx.doi.org/10.18632/oncotarget.11588

Ejemplares similares

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
por: Knudsen, Erik S., et al.
Publicado: (2017)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015)

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2014)

Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
por: Franco, Jorge, et al.
Publicado: (2020)

Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
por: Kumarasamy, Vishnu, et al.
Publicado: (2019)

Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer
por: McDermott, Martina S.J., et al.
Publicado: (2017)

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
por: Franco, Jorge, et al.
Publicado: (2014)

Determinants of response to CDK4/6 inhibitors in the real-world setting
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2023)

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
por: Gopalan, Priya K., et al.
Publicado: (2018)

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells
por: Fleyshman, Daria, et al.
Publicado: (2017)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017)

Cell cycle plasticity driven by MTOR signaling: Integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
por: Knudsen, Erik S., et al.
Publicado: (2019)

Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes
por: Messier, Terri L., et al.
Publicado: (2016)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
por: Knudsen, Erik S., et al.
Publicado: (2022)

Loss of p16(INK4A) stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway
por: Tyagi, Ethika, et al.
Publicado: (2017)

AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
por: Jhaveri, Teraneh Z., et al.
Publicado: (2015)

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
por: Jin, Xi, et al.
Publicado: (2020)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
por: Ladd, Brendon, et al.
Publicado: (2016)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
por: Portman, Neil, et al.
Publicado: (2020)

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
por: Soares, Maria, et al.
Publicado: (2016)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
por: Behrouzi, Roya, et al.
Publicado: (2023)

The emerging role of CDK4/6i in HER2-positive breast cancer
por: O’Sullivan, Ciara C., et al.
Publicado: (2019)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
por: Tang, Hiu, et al.
Publicado: (2023)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer
por: Yang, Wei, et al.
Publicado: (2018)

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
por: Witkiewicz, Agnieszka K, et al.
Publicado: (2014)

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
por: Sun, Bowen, et al.
Publicado: (2019)

CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents
por: Liao, Hongwei, et al.
Publicado: (2017)

p16(INK4A)-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases
por: Ni, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9g3b3ak7a40q8hnighiejjb8tf